novel agents for consolidation after auto-sct in myeloma
Published 3 years ago • 65 plays • Length 3:15Download video MP4
Download video MP3
Similar videos
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
3:24
novel agents for the management of r/r myeloma
-
2:22
the benefit of autologous transplantation in the era of novel agents in multiple myeloma
-
1:15
bringing novel agents to the frontline setting in myeloma
-
1:17
novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
-
2:13
novel agents in development for multiple myeloma: celmods, antibody-drug conjugates, and peptides
-
2:57
novel targeted therapies for the treatment of bpdcn
-
2:44
novel bcma-targeting therapies to treat tce relapsed/refractory multiple myeloma
-
1:27
the use of salvage second autologous transplant in the age of novel therapies for multiple myeloma
-
1:50
the value of moving novel agents into the frontline setting in all
-
4:03
novel technologies in multiple myeloma and how these are changing the field
-
1:18
how will novel agents be sequenced for patients with multiple myeloma?
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
1:02
novel agents in multiple myeloma: considering toxicity and side effects
-
1:53
how novel agents may eliminate the need for transplant in all
-
0:56
new additions: novel agents to boost treatment of multiple myeloma
-
1:01
car-t: myeloma toxicities
-
2:42
novel agents in the post-bcma space in myeloma